GSK, endometrial cancer and chemotherapy

EC approves GSK’s Jemperli-chemo combo for endometrial cancer
"EC approves GSK’s Jemperli-chemo combo for endometrial cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on t
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or recurrent endometrial cancer.
Europe Drug Regulator Expands GSK's Jemperli/Chemo Combo To Adult Patients With Advanced Endometrial Cancer
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.
EU approves endometrial, lung cancer drugs from GSK and J&J
Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first-line treatment for locally advanced and metastatic NSCLC with exon 19 deletions or exon 21 L858R substitutions.
GSK announces expanded EU approval in endometrial cancer for Jemperli combo
GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of
GSK’s Jemperli combination approved by EC for expanded endometrial cancer use
GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU to treat certain adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer.
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer
European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0
GSK gets European Commission nod for expanded use of Jemperli in endometrial cancer
London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult
Medscape1d
Does Chemoradiotherapy Boost Survival in Endometrial Cancer?
The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial ...
Report: Cancer risk for women under 65 higher than men in same age group
The risk and incidence of cancer among people under 50 is also on the rise, according to American Cancer Society.
Cure Today12d
First-Line Lenvima Plus Keytruda Misses Mark in Endometrial Cancer
For patients with advanced or recurrent endometrial cancer, first-line Lenvima plus Keytruda didn’t significantly improve ...
MedPage Today13d
Concerning Trends in Endometrial Cancer
—A new study from California-based researchers reports that things may be getting worse for certain women at risk for endometrial cancer. Here’s what the research team adds to what’s known ...